Navigation Links
New drug shows promise for those with clotting disorders: McMaster researcher
Date:12/6/2009

Hamilton, ON. Dec. 6, 2009 A new study provides welcome news for patients with a common clotting disorder known as venous thromboembolism (VTE).

The condition is estimated to impact 62,000 Canadians and half-a-million Americans every year, and occurs when an abnormal clot forms in a vein and restricts the flow of blood, causing pain and swelling. In some cases, the clot may detach from its point of origin and travel through the heart to the lungs, causing a potentially fatal condition known as a pulmonary embolism.

Currently, patients with VTE are treated with a blood thinner known as warfarin, which has many burdensome interactions with other medications and foods and requires frequent monitoring of the dosage.

However, this study published today shows that an oral drug called dabigatran etexilate, which does not have these disadvantages, is as safe and effective as warfarin for combating VTE.

To compare the two drugs, an international team of researchers lead by Sam Schulman, a professor of medicine of the Michael G. DeGroote School of Medicine, who conducted a randomized, double-blind trial of 2,539 patients with acute VTE.

Today, Schulman is scheduled to present this study to the annual conference of the American Society of Hematology in New Orleans, LA, and the New England Journal of Medicine will post the study on its web site. The study will be published in the Dec. 10 edition of the New England Journal of Medicine.

For six months, roughly half of the patients in the trial (1,274) were given a fixed dose of 150 mg of dabigatran etexilate twice daily, while the other half (1,265 patients) were given warfarin once daily.

The improvement seen in both groups from the treatments was similar. After six months of treatment, only 2.4 percent of the dabigatran etexilate group (30 patients) and 2.1 percent of the warfarin group (27 patients) experienced recurrent VTE.

The safety of the two drugs was also comparable. In the dabigatran etexilate arm, 205 patients experienced bleeding (including 20 patients with major bleeding) versus 277 patients in the warfarin arm (including 24 with major bleeding). Other possible side effects, including death, acute coronary syndromes, and abnormalities in liver function tests, were infrequent in the two groups.

"We are excited by these findings and feel that they will change the standard of care for venous thromboembolism, which affects a large number of our patients," said Schulman, a physician with the thrombosis service of Hamilton Health Sciences. "This study found that dabigatran is a safe and effective anticoagulant that does not require the routine monitoring or dose adjustments that are necessary with warfarin. In other words, patients can receive the same results in a more convenient manner."


'/>"/>

Contact: Susan Emigh
emighs@mcmaster.ca
905-518-3642
McMaster University
Source:Eurekalert

Related medicine news :

1. Congress Has Allowed Most Previous Medicare Cuts to Take Effect, New Study Shows
2. NYU Langone Medical Center Study Shows VNS Therapy is a Safe and Effective Treatment for Refractory Epilepsy
3. New Actuarial Analysis Shows Senate Bill Would Significantly Raise Premiums
4. New Hepatitis C Treatment Shows Promise
5. Report shows CIMT may improve arm use in children with hemiplegic cerebral palsy
6. Alcohol companies target youths with magazine ads, new study shows
7. Study shows modest improvement in advanced lung cancer overall survival rates
8. New Survey Shows Overwhelming Support Among Latinos for Health Care Reform That Includes Public Option
9. Brain scan study shows cocaine abusers can control cravings
10. Study shows new brain connections form rapidly during motor learning
11. Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Milwaukee, WI (PRWEB) , ... March 29, 2017 , ... ... as its exclusive provider of co-op eligible dealer websites for its network of more ... line of professional landscaping and agricultural equipment including rotary and flail mowers and cutters, ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... professional squash, announced it has enlisted New York City-based sports and entertainment marketing ... develop and procure sponsorship opportunities for the Professional Squash Association (PSA), which includes ...
(Date:3/29/2017)... ... March 30, 2017 , ... Grass pollen is the main cause of hay fever in ... The season for grass pollen runs from May to July each year; with the worst ... to do? HayMax™ allergen barrier balms ( http://www.haymax.us ) provide an effective defense against grass ...
(Date:3/29/2017)... Amherst, Massachusetts (PRWEB) , ... March 30, 2017 , ... ... has had great success and feedback from high school and college students who have ... is being held July 7-23 and YFI is now accepting applications for enrollment. ...
(Date:3/29/2017)... , ... March 30, 2017 , ... Sports Brand EXOUS ... brace, which retails normally at $29.97; for the remaining days of March, the price ... been reduced to a special price of just $10 (regular retail price $19.97). , ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 2017 Research and Markets has announced the ... to their offering. ... The global gas chromatograph market to grow at a CAGR ... Global Gas Chromatograph Market 2017-2021, has been prepared based on an ... the market landscape and its growth prospects over the coming years. ...
(Date:3/29/2017)... 29, 2017  Novartis announced today that the ... the company,s Biologics License Application (BLA) filing and ... chimeric antigen receptor T cell (CAR-T) therapy, in ... patients with B-cell acute lymphoblastic leukemia (ALL). This ... a CAR-T. The priority review designation is expected ...
(Date:3/29/2017)... Research and Markets has announced the addition of the ... Centers & Forecast" report to their offering. ... The South Korean Proton Therapy Market is expected ... The Untapped Proton Therapy Market for South Korea ... Proton Therapy plays an important role in delivering comprehensive cancer care ...
Breaking Medicine Technology: